[Testing of cellular immune reactivity in melanoma patients with diphenylcyclopropenone in comparison to dinitrochlorobenzol].
Ten patients with malignant melanoma were simultaneously sensitized with dinitrochlorobenzol (DNCB) and diphenylcyclopropenon (DPCP) (500 micrograms each). Fourteen days after sensitization the patients were challenged with 0.04-25 micrograms doses of DNCB and DPCP. The reactions of all of the subjects tested were the same for DNCB as for DPCP. The results were statistically significant. To achieve a skin reaction of the same intensity, the necessary doses of DPCP were much lower than those of DNCB.